title: [Thiotriazoline in the Treatment of Stable Angina IIIII Functional Class].
abstract: Trimetazidine is a metabolic agent of proven efficacy in improving myocardial ischemia and angina. A comparative international multicenter randomized trial, assessed anti-anginal anti ischemic efficacy and safety of Trimetazidine (60 mg/d) and Thiotriazoline (600 mg/d) in symptomatic patients with chronic ischemic heart disease receiving the first line therapy. The study assessed the efficacy of the two drugs on total exercise duration, time to 1-mm ST segment depression, the number of angina attacks and nitroglycerin tablets consumed amount. Both drugs have demonstrated clinical efficacy equal for all primary and secondary endpoints.
authors.affiliation: 1S.. Kirov St. Petersburg Military medical academy, St. Petersburg, Russia; 2St.Petersburg State University, St. Petersburg, Russia.
authors.forename: D V
authors.initials: DV
authors.lastname: Kadin
authors.affiliation: 1S.. Kirov St. Petersburg Military medical academy, St. Petersburg, Russia; 2St.Petersburg State University, St. Petersburg, Russia.
authors.forename: B A
authors.initials: BA
authors.lastname: Chumak
authors.affiliation: 1S.. Kirov St. Petersburg Military medical academy, St. Petersburg, Russia; 2St.Petersburg State University, St. Petersburg, Russia.
authors.forename: A E
authors.initials: AE
authors.lastname: Filippov
authors.affiliation: 1S.. Kirov St. Petersburg Military medical academy, St. Petersburg, Russia; 2St.Petersburg State University, St. Petersburg, Russia.
authors.forename: S B
authors.initials: SB
authors.lastname: Shustov